Your session is about to expire
← Back to Search
Anticoagulant
rivaroxaban for Portal Vein Thrombosis
Phase 3
Waitlist Available
Research Sponsored by Università degli Studi dell'Insubria
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.
Eligible Conditions
- Portal Vein Thrombosis
- Mesenteric Vein Thrombosis
- Splenic Vein Thrombosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Major bleeding
Trial Design
1Treatment groups
Experimental Treatment
Group I: rivaroxabanExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban
FDA approved
Find a Location
Who is running the clinical trial?
Università degli Studi dell'InsubriaLead Sponsor
76 Previous Clinical Trials
19,888 Total Patients Enrolled
Ottawa Hospital Research InstituteOTHER
563 Previous Clinical Trials
2,787,617 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger